MedTrace Logo

Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge

NCT02622243 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2016-04-20

No results posted yet for this study

Summary

The study will assess the duration of protection of single doses of 2 different long acting muscarinic antagonists against methacholine induced bronchoconstriction.

Conditions

Interventions

DRUG

Tiotropium

long acting muscarinic antagonist

DRUG

glycopyrronium

long acting muscarinic antagonist

DEVICE

Respimat

inhaler device used to deliver active tiotropium or placebo

DEVICE

Breezehaler

inhaler device used to deliver active glycopyrronium or placebo

Sponsors & Collaborators

  • University of Saskatchewan

    lead OTHER

Principal Investigators

  • Don Cockcroft, MD · University of Saskatchewan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02622243 on ClinicalTrials.gov